Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development. In this study, the authors report a mutation that increases the production of recombinant SARS-CoV-2 Spike and exposure of the RBD. In animal models, a Spike-based vaccine containing the mutation induces strong immunogenicity, provides protection from disease and results in faster tissue viral clearance.
Proyecto:
Generalitat de Catalunya SLD0015
,
Generalitat de Catalunya 2020 FI_B_0742
,
Generalitat de Catalunya 2020FI_B2_00138
,
Generalitat de Catalunya 2022 FI_B_00698
,
Generalitat de Catalunya SLD0016
,
Generalitat de Catalunya 2021SGR00452
,
Instituto de Salud Carlos III PI18/01332
,
Instituto de Salud Carlos III PI17/01518
,
Agencia Estatal de Investigación PID2020-117145RB-I00